ELISpot/FluoroSpot 檢測的全球市場：市場規模和佔有率分析（依產品類型、應用和最終用戶）、工業需求預測（截至 2030 年）

預計 2023 年全球 ELISpot/FluoroSpot 檢測市場規模將達到 2.895 億美元，2024 年至 2030 年複合年增長率為 7.9%，到 2030 年將達到 4.908 億美元。

檢測試劑盒佔比最大

由於傳染病和慢性病的流行以及檢測試劑盒的相關開發，檢測試劑盒可能會在本十年末引領市場。

ELISpot 檢測用於檢查疫苗針對幹擾素、發炎介質和白血球介素等免疫介質的效率。 此外，此測定的主要優點是成本效益高且結果顯示迅速。

醫院和診所是主要的最終使用者

2023 年，醫院和診所的市佔率最大，達 60%。 這是因為許多患者首選醫院和診所進行疾病診斷，特別是在新興國家。

北美是市場領導者

到 2023 年，北美將佔據 55% 的佔有率，成為依地區劃分的最大市場。 根據美國人口普查局的數據，美國約有 5,600 萬 65 歲及以上的成年人，約佔全國總人口的 16.9%。

中國引領亞太市場

在亞太地區，中國將成為成長最快的市場。 這主要是由於癌症和其他慢性疾病的流行、對研發活動的日益重視、患者數量的增加以及醫療保健支出的迅速增加。

在本報告中，我們分析了全球 ELISpot/FluoroSpot 檢測市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、依地區和主要國家的市場規模前景（金額（2017-2030 ），依產品類型、應用和最終用戶劃分的詳細趨勢、市場競爭現狀以及主要公司概況。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

• 摘要
• 市場收入：依產品類型劃分（2017-2030 年）
• 市場收入：依應用分類（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其提供的產品/服務的列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• Oxford Immunotec
• Cellular Technology Limited
• Mabtech AB
• Becton, Dickinson and Company
• Bio-Techne Corporation

第31章附錄

The value of the ELISpot and FluoroSpot assay market was USD 289.5 million in 2023, and it will power at a compound annual growth rate of 7.9% during 2024-2030, to touch USD 490.8 million by 2030.

Market Drivers

Some driving factors of the industry are the growing occurrence of infectious and chronic diseases at a global level, particularly HIV, and the growing elderly population.

ELISpot and FluoroSpot are performed for several diseases, for instance, cancer, infectious diseases, and, autoimmune ailments. The ELISpot assay clearly spots the number of cytokine-secreting cell with high specialty and sensitivity.

These benefits make it an effective tool for measuring the degree of adaptive and innate immune responses.

As stated by the CDC's NCEZID, the infectious disease risk is increasing incessantly due to the change in climate all over the world.

Lyme disease, Valley fever, and West Nile disease are some infectious diseases, rising in prevalence and spreading to novel regions of the U.S. This is because of the warmer summers, milder winters, and fewer days with frost.

Assay Kits Hold Largest Share

Assay kits will lead the market by the end of this decade because of the growing incidence of infectious and chronic ailments, accompanied by the development in assay kits.

The ELISpot assay is used to examine the vaccine efficiency on immune mediators, for example, interferons, pro-inflammatory mediators, and interleukins. Additionally, the main benefit of this assay is that it is cost-effective and displays results quickly.

Hospitals and Clinics are the Major End Users

Hospitals and clinics were the leaders of the market, with a share of 60%, in 2023. This is because hospitals and clinics and preferred by most patients for disease diagnosis, particularly in emerging countries.

Furthermore, with continued efforts of the government, the count of such medical centers is on the rise, at a global level, which drives the demand for all sorts of therapeutic and diagnostic equipment at these places.

For addressing the huge demand for biopharmaceuticals, there is a growing emphasis on research and, related spending. The capability of biopharmaceuticals for treating ailments that were incurable before has brought about the release of these kinds of new medications in the market.

Therefore, the market under investigation will grow by the end of this decade.

North America is the Leader of the Market

North America was the regional leader of the market, with a 55% share, in 2023. As per the U.S. Census Bureau, approximately 56 million adults aged 65 or more are in the U.S. and make about 16.9% of the total population of the country.

Further, there will be over 73 million older adults by the time 2030 comes to an end, which means over 20% of people will be older. The total count of adults aged 65 and more will increase to 85.7 million by 2050 and will comprise 22% of the total population of the nation.

China Leads the Pack in the APAC Market

In the APAC region, China will be the fastest-growing market. This has a lot to do with the prevalence of cancer and other chronic ailments, increasing emphasis on research and development activities, rising patient populace, and surging healthcare spending.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Oxford Immunotec
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Cellular Technology Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Mabtech AB
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Becton, Dickinson and Company
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Bio-Techne Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports